
Guido Oelkers to Depart Sobi CEO Role in 2027
After a decade at the helm of Swedish Orphan Biovitrum AB, CEO Guido Oelkers has notified the board of his intent to resign. The executive will remain in his position through January 2027, allowing the company to initiate a search for a successor to maintain continuity in its rare disease strategy.




















